Stocklytics Platform
Asset logo for symbol SLNO
Soleno Therapeutics
SLNO64
$48.43arrow_drop_up3.15%$1.48
High Growth
Asset logo for symbol SLNO
SLNO64

$48.43

arrow_drop_up3.15%

Performance History

Chart placeholder
Key Stats
Open$47.60
Prev. Close$46.95
EPS-2.07
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range47.56
49.28
52 Week Range3.69
53.82
Ratios
Revenue-
EBITDA Margin %-
EPS-2.07

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Asset logo for symbol LLY
Eli Lilly & Co
LLY74
Price$804.62
Perf. (24h)
arrow_drop_down2.01%-$16.57
Market Cap$738.87B
Asset logo for symbol UNH
UnitedHealth Group
UNH71
Price$569.71
Perf. (24h)
arrow_drop_up1.79%$10.03
Market Cap$527.83B
Asset logo for symbol JNJ
Johnson & Johnson
JNJ62
Price$160.64
Perf. (24h)
arrow_drop_up0.62%$1.00
Market Cap$386.60B
Asset logo for symbol ABBV
AbbVie
ABBV62
Price$185.16
Perf. (24h)
arrow_drop_up1.64%$2.99
Market Cap$326.96B

About Soleno Therapeutics (SLNO)

Soleno Therapeutics Inc (SLNO) is a healthcare company focused on the development and commercialization of novel therapeutics for rare diseases. The company’s primary focus is on the treatment of Prader-Willi Syndrome (PWS), a genetic disorder characterized by hyperphagia, or insatiable appetite leading to obesity, as well as cognitive and behavioral problems. Soleno’s lead product candidate, DCCR (diazoxide choline controlled-release), is a proprietary once-daily oral tablet that is designed to address the underlying causes of PWS. The company is currently conducting a Phase III clinical trial of DCCR in patients with PWS.
Soleno Therapeutics Inc (SLNO) was founded in 1999 and is headquartered in Redwood City, California. The company’s mission is to improve the lives of patients with rare diseases by developing innovative therapies that target the underlying causes of these conditions. Soleno’s approach is based on a deep understanding of the science behind the diseases it targets, as well as strong partnerships with leading researchers and healthcare professionals. The company is committed to delivering safe and effective therapies that can make a meaningful difference in the lives of patients and their families.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Anish Bhatnagar M.D.
Headquarters
Redwood City
Employees
25
Exchange
NASDAQ
add Soleno Therapeutics to watchlist

Keep an eye on Soleno Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Soleno Therapeutics 's (SLNO) price per share?
The current price per share for Soleno Therapeutics (SLNO) is $48.43. The stock has seen a price change of $1.48 recently, indicating a 3.15% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Soleno Therapeutics (SLNO)?
For Soleno Therapeutics (SLNO), the 52-week high is $53.82, which is 11.13% from the current price. The 52-week low is $3.69, the current price is 1.21K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Soleno Therapeutics (SLNO) a growth stock?
Soleno Therapeutics (SLNO) has shown an average price growth of 0.41% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Soleno Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Soleno Therapeutics (SLNO) stock price performance year to date (YTD)?
As of the latest data, Soleno Therapeutics (SLNO) has a year-to-date price change of 27.62%. Over the past month, the stock has experienced a price change of 22.42%. Over the last three months, the change has been 27.82%. Over the past six months, the figure is 3.93%. Looking at a longer horizon, the five-year price change stands at 41.61%.
help
Is Soleno Therapeutics (SLNO) a profitable company?
Soleno Therapeutics (SLNO) has a net income of -$38.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.67M. Furthermore, the EBITDA is -$51.62M.
help
What is the market capitalization of Soleno Therapeutics (SLNO)?
Soleno Therapeutics (SLNO) has a market capitalization of $1.8B. The average daily trading volume is 305.84K, indicating the stock's liquidity and investor engagement.

News

Soleno Therapeutics enters agreement to sell $150 million in stock By Investing.com - Investing.com Canada
SOLENO THERAPEUTICS
JEFFERIES LLC
MEDICAL DEVICE
STOCK SALE
7/20/2024

Soleno Therapeutics enters agreement to sell $150 million in stock By Investing.com - Investing.com Canada

Soleno therapeutics exec sells over $90k in stock By Investing.com - Investing.com
SOLENO THERAPEUTICS
INSIDER TRADING
STOCK SALE
RESTRICTED STOCK UNITS
7/3/2024

Soleno therapeutics exec sells over $90k in stock By Investing.com - Investing.com

Soleno therapeutics executive sells over $90k in stock By Investing.com - Investing.com
SOLENO THERAPEUTICS
INSIDER TRADING
STOCK SALE
REGULATORY AFFAIRS
7/3/2024

Soleno therapeutics executive sells over $90k in stock By Investing.com - Investing.com

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
HEALTH
MANAGEMENT STATEMENTS
6/28/2024

Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHANGES IN COMPANY'S OWN SHARES
6/24/2024

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
CALENDAR OF EVENTS
PRODUCT / SERVICES ANNOUNCEMENT
5/22/2024

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level